Thrombotic Thrombocytopenic Purpura

Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially life-threatening disorder that affects the body’s ability to produce platelets, the tiny cells that help control bleeding. It is caused by a deficiency in a protein called ADAMTS13, which results in the formation of platelet clots in small blood vessels throughout the body, including the brain, kidneys, and other organs. TTP can lead to serious complications such as thrombotic microangiopathy, stroke, organ failure, and death without prompt and appropriate treatment. Treatment for TTP often involves the use of plasma exchange, a procedure in which the patient’s plasma is removed and replaced with donor plasma, to replenish the deficient ADAMTS13 protein. Plasma exchange is considered the most effective treatment for TTP, as it can prevent further blood clots and reduce the risk of irreversible organ damage.